Piper Sandler Maintains Overweight on Sage Therapeutics, Lowers Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Sage Therapeutics (NASDAQ:SAGE) but lowers the price target from $70 to $52.
August 01, 2024 | 5:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Sage Therapeutics but lowers the price target from $70 to $52.
The lowered price target from $70 to $52 suggests a less optimistic outlook for Sage Therapeutics, which could negatively impact the stock price in the short term despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100